X4 Pharmaceuticals (XFOR) Income towards Parent Company (2017 - 2025)
X4 Pharmaceuticals (XFOR) posted Income towards Parent Company of -$23.9 million for Q4 2025, up 19.76% on a QoQ basis from -$29.8 million in Q3 2025, and up 39.92% year-over-year from -$17.1 million in Q4 2024.
X4 Pharmaceuticals (XFOR) Income towards Parent Company (2017 - 2025) Analysis & Trends
X4 Pharmaceuticals' Income towards Parent Company history runs 9 years deep, the most recent figure standing at -$23.9 million for Q4 2025.
- Quarterly Income towards Parent Company rose 39.92% year-over-year to -$23.9 million in Q4 2025, while the trailing twelve-month figure through Dec 2025 was -$79.2 million (down 111.48% YoY) and the FY2025 annual result came in at -$79.2 million, down 111.48% from the prior year.
- Income towards Parent Company was -$23.9 million for Q4 2025 at X4 Pharmaceuticals, up from -$29.8 million in the prior quarter.
- Across five years, Income towards Parent Company topped out at $90.8 million in Q2 2024 and bottomed at -$55.7 million in Q2 2023.
- A 5-year average of -$20.0 million and a median of -$22.9 million in 2022 frame the typical range for Income towards Parent Company.
- Peak annual rise in Income towards Parent Company reached 263.04% in 2024, while the deepest fall reached 1492.02% in 2024.
- X4 Pharmaceuticals' Income towards Parent Company stood at -$30.2 million in 2021, then increased by 3.65% to -$29.1 million in 2022, then jumped by 34.27% to -$19.1 million in 2023, then tumbled by 108.16% to -$39.8 million in 2024, then jumped by 39.92% to -$23.9 million in 2025.
- Business Quant data shows XFOR's Income towards Parent Company at -$23.9 million in Q4 2025, -$29.8 million in Q3 2025, and -$25.7 million in Q2 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Oculis Holding AG | 66,621.14 Bn | 66,620.85 Bn | - |
| 2 | Nanobiotix | 1,915.18 Bn | 1,915.11 Bn | - |
| 3 | Akari Therapeutics | 1,014.18 Bn | 1,014.18 Bn | - |
| 4 | BeOne Medicines | 471.27 Bn | 466.48 Bn | 1.35 Bn |
| 5 | Vertex Pharmaceuticals | 121.81 Bn | 114.57 Bn | 2.59 Bn |
| 6 | Regeneron Pharmaceuticals | 69.58 Bn | 60.82 Bn | 3.31 Bn |
| 7 | Belite Bio | 62.72 Bn | 62.72 Bn | - |
| 8 | Argenx Se | 55.51 Bn | 50.33 Bn | 1.41 Bn |
| 9 | Revolution Medicines | 37.35 Bn | 37.35 Bn | - |
| 10 | X4 Pharmaceuticals | 167.90 Mn | -49.15 Mn | 2.20 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | -23.93 Mn |
| Sep 30, 2025 | -29.82 Mn |
| Jun 30, 2025 | -25.74 Mn |
| Mar 31, 2025 | 282,000.00 |
| Dec 31, 2024 | -39.82 Mn |
| Sep 30, 2024 | -36.70 Mn |
| Jun 30, 2024 | 90.83 Mn |
| Mar 31, 2024 | -51.77 Mn |
| Dec 31, 2023 | -19.13 Mn |
| Sep 30, 2023 | -2.31 Mn |
| Jun 30, 2023 | -55.71 Mn |
| Mar 31, 2023 | -24.02 Mn |
| Dec 31, 2022 | -29.10 Mn |
| Sep 30, 2022 | -21.59 Mn |
| Jun 30, 2022 | -21.21 Mn |
| Mar 31, 2022 | -21.97 Mn |
| Dec 31, 2021 | -30.21 Mn |
| Sep 30, 2021 | -20.18 Mn |
| Jun 30, 2021 | -19.64 Mn |
| Mar 31, 2021 | -18.68 Mn |